GLAXO NSI Week ended 07 Aug 2026

Weekly Investor Report

GlaxoSmithKline Pharmaceuticals Limited · Healthcare · Drug Manufacturers - General

Open interactive chart View report data
Latest close 2,600 INR
-2.1% latest week
Weekly setup

Mixed setup

The weekly trend is not active. Price is 8.6% above the Trend Line and sits at 64.3% of its 52-week range. The latest completed week returned -2.1%, after a 6.6% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is expensive relative to peers. The latest news-sentiment score is 50/100.

Setup score 55 out of 100
Latest Close 2,600 INR 7 Aug 2026
1W Return -2.1% latest completed week
4W Return 6.6% short-term follow-through
12W Return 9.3% quarterly tape
Trend Breadth 1.9% 1 of 52 weeks active
Volume Ratio 1.0x vs 13-week average
What is working
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Activity pressure is weak, so confirmation is not yet broad enough.
  • Latest weekly return ranks in the weaker part of its sector group.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -2.1% Latest completed week; four-week move 6.6%. Indicator stack 1/85 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 50/100 13 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is 8.6% above the Trend Line and sits at 64.3% of its 52-week range. The latest completed week returned -2.1%, after a 6.6% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.0x the 13-week average. Participation is around or above normal and provides reasonable confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.2112-week average 0.08

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure6/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership3/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.21Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 6.6% over four weeks, 9.3% over 12 weeks, and -1.9% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-2.1%
4W6.6%
12W9.3%
26W4.7%
52W-1.9%
Active trend streak0 weeks
Active weeks in one year1
Trend breadth1.9%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.38Latest activity-pressure read.
Pressure change133.9%Four-week change in activity pressure.
Leadership4.83Latest relative-leadership reading.
RS change465.6%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is expensive relative to peers.

Open full factor analysis
Factor week 09 Aug 2026 Financial statements through 31 Mar 2026 Field coverage 94% Model confidence 88%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength24/100Blend of value, momentum, and quality. Underlying universe rank 77; rank 1 is best.
Value12/100Relative valuation strength. Underlying universe rank 89; rank 1 is best.
Quality98/100Profitability and accounting quality. Underlying universe rank 3; rank 1 is best.
Momentum36/100Medium-term price momentum. Underlying universe rank 65; rank 1 is best.
Growth25/100Revenue and earnings growth. Underlying universe rank 76; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
42.3x
Price divided by trailing earnings.
Price / sales
11.5x
Market value relative to trailing revenue.
EV / EBITDA
29.1x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
2.0%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
64.7%
Gross profit retained from each unit of revenue.
Operating margin
32.6%
Operating profit retained from revenue.
Free-cash-flow margin
22.2%
Free cash flow generated from revenue.
Return on invested capital
77.8%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
2.2%
Latest one-year revenue growth.
EPS growth
11.7%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-33.0%
Latest one-year free-cash-flow growth.
Piotroski F-score
6/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
2.2%
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
2.2%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-0.7x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment50/100

Weighted news tone is neutral across 13 relevant articles.

2 positive · 11 neutral · 0 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-9.8%Distance below the 52-week high.
13-week volatility3.8%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher13 of 2613 weeks finished lower.
Best week+9.9%Week of 19 Jun.
Worst week-5.5%Week of 1 May.
Latest week-2.1%Week of 7 Aug.

Shape of recent returns

Strong gains4
Modest gains9
Flat weeks0
Modest losses10
Sharp losses3
Recent vol3.8%13-week weekly-return volatility.
Base vol3.1%52-week weekly-return volatility.
Up/down split25/27Count of positive and negative weeks in the 52-week window.
Average skew2.6% / -2.4%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape50/100

Trend, activity pressure, participation, and risk combine to a 50/100 tape read.

 Indicator analysis27/100

Latest 12-week confirmation: trend 0/12, activity pressure 6/12, relative leadership 3/12.

Activity pressure 0.21; No reversal markers Factors42/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 34 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment50/100

Weighted news tone is neutral across 13 relevant articles.

GlaxoSmithKline Pharmaceuticals Schedules Board Meeting on May 13, 2026 for FY26 Results Approval Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
7 Aug 20262,600 INR-2.1%2,395 INR2,383 INR1.384.83315.7KOff
31 Jul 20262,655 INR5.6%2,387 INR2,376 INR1.357.83416.0KOff
24 Jul 20262,514 INR2.4%2,382 INR2,367 INR1.154.54325.3KOff
17 Jul 20262,455 INR0.7%2,380 INR2,360 INR0.91-0.70409.8KOff
10 Jul 20262,438 INR1.8%2,382 INR2,353 INR0.59-1.32290.4KOff
3 Jul 20262,396 INR1.7%2,388 INR2,346 INR-0.01-3.8257.1KOff
26 Jun 20262,355 INR1.0%2,393 INR2,339 INR-0.54-5.140Off
19 Jun 20262,332 INR9.9%2,400 INR2,333 INR-0.73-6.53252.0KOff
12 Jun 20262,122 INR-2.0%2,406 INR2,327 INR-0.81-14.05357.5KOff
5 Jun 20262,164 INR-2.1%2,417 INR2,322 INR-0.51-12.0728.7KOff
29 May 20262,210 INR-1.8%2,432 INR2,316 INR-0.06-11.61751.0KOff
22 May 20262,250 INR-5.4%2,445 INR2,310 INR0.07-11.32518.8KOff
15 May 20262,378 INR-1.5%2,462 INR2,304 INR0.21-6.37356.1KOff
8 May 20262,415 INR6.0%2,474 INR2,296 INR0.20-7.18485.6KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context